TransCode Therapeutics announces 1-for-28 reverse stock split effective May 15, 2025

Transcode Therapeutics, Inc.

Reverse split at 1-for-28 ratio; effective 12:01 a.m. ET on May 15, 2025.
Outstanding shares reduced from 23,341,336 to approximately 833,620; par value unchanged.
No fractional shares issued; rounding up to nearest whole share for record holders.
Split intended to meet Nasdaq minimum bid price requirement; CUSIP changes to 89357L501.
Stockholder approval obtained May 2, 2025; trading symbol remains RNAZ.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Transcode Therapeutics, Inc.: Filed a Certificate of Amendment to effect a 1-for-28 reverse stock split of common stock, effective May 15, 2025 (effective 2025-05-15).

Change: charter amendment
Effective: 2025-05-15

Exact text from the filing

On May 5, 2025, TransCode Therapeutics, Inc., (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation to effect a 1-for-28 reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), as of 12:01 a.m. Eastern Time on May 15, 2025 (the “Effective Time”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-044596

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.